Status:
COMPLETED
Smoking Treatment of Prisoners
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Tobacco Use Cessation
Tobacco Use Disorder
Eligibility:
FEMALE
18-100 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.
Detailed Description
This is a randomized controlled trial utilizing a wait-list control group to examine 10-week group therapy and nicotine replacement compared to wait-list for smoking cessation among female prisoners.
Eligibility Criteria
Inclusion
- 1\) current smoker and (2) seeking group treatment to quit smoking.
Exclusion
- (1) non-english speaking, (2) housed in segregation, (3) presence of active, severe mental illness as defined by active psychosis, manic episode, or imminently suicidal/homicidal, (4) mental retardation such that they cannot provide informed consent, and (5) due to be released or transferred to another facility within the next year.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00110630
Start Date
June 1 2005
End Date
September 1 2007
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298